0001562180-24-004106.txt : 20240516 0001562180-24-004106.hdr.sgml : 20240516 20240516171951 ACCESSION NUMBER: 0001562180-24-004106 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240514 FILED AS OF DATE: 20240516 DATE AS OF CHANGE: 20240516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GUYER DAVID R CENTRAL INDEX KEY: 0001277476 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 24956802 MAIL ADDRESS: STREET 1: ONE PENN PLAZA, 19TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-05-14 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001277476 GUYER DAVID R C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 true false false false true Common Stock 2024-05-14 4 M false 6525.00 3.26 A 13925.00 D Common Stock 2024-05-14 4 M false 3250.00 3.50 A 17175.00 D Common Stock 2024-05-14 4 S false 11625.00 12.649 D 5550.00 D Stock Option (Right to Buy) 3.50 2024-05-14 4 M false 3250.00 0.00 D 2024-02-23 2033-06-19 Common Stock 3250.00 9750.00 D Stock Option (Right to Buy) 3.26 2024-05-14 4 M false 6525.00 0.00 D 2024-01-06 2033-06-19 Common Stock 6525.00 19575.00 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.44 to $12.83. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Ron Honig, Attorney-in-Fact 2024-05-16